Financial health
- Operating income covered interest expense -107.9× in the latest year.
CTOR Financials CITIUS ONCOLOGY, INC.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Net income
ROEROA
Equity
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$25M | — | — | -55.2% | -24.5% | — | — | $4M |
| 2024 | — | -$21M | — | — | -45.8% | -25.1% | — | — | $112 |
| 2023 | — | $2M | — | — | 10.6% | 3.3% | — | — | — |
| 2023 | — | -$13M | — | — | -49.7% | -26.6% | — | — | — |
| 2022 | — | $380811 | — | — | 110.2% | 0.6% | — | — | — |
| 2021 | — | -$10113 | — | — | 100.0% | -8.0% | — | — | — |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $1M | -$9M | 67.1% | -583.5% | -22.1% | -8.0% | — | — | $17M |
| Mar '26 | $2M | -$27M | 80.3% | -1716.2% | -75.4% | -26.4% | — | — | $3M |
| Dec '25 | $4M | -$6M | 80.0% | -133.2% | -9.5% | -5.0% | — | — | $7M |
| Sep '25 | — | -$5M | — | — | -11.1% | -4.9% | — | — | $4M |
| Jun '25 | — | -$5M | — | — | -16.6% | -5.9% | — | — | $112 |
| Mar '25 | — | -$8M | — | — | -21.7% | -8.5% | — | — | $112 |
| Dec '24 | — | -$7M | — | — | -16.1% | -7.4% | — | — | — |
| Sep '24 | — | -$7M | — | — | -14.8% | -8.1% | — | — | $112 |
| Jun '24 | — | -$5M | — | — | -28.0% | -9.7% | — | — | — |
| Mar '24 | — | -$5M | — | — | -24.4% | -9.9% | — | — | — |
| Dec '23 | — | -$5M | — | — | -20.8% | -6.5% | — | — | — |
| Sep '23 | — | $157943 | — | — | 0.6% | 0.3% | — | — | — |
| Jun '23 | — | $616296 | — | — | -31315.9% | 0.9% | — | — | — |
| Mar '23 | — | $611725 | — | — | 309.6% | 0.9% | — | — | — |
| Dec '22 | — | $390924 | — | — | 113.1% | 0.6% | — | — | — |
| Dec '21 | — | $0 | — | — | 0.0% | 0.0% | — | — | — |
| Sep '21 | — | -$9389 | — | — | 92.8% | — | — | — | — |
| Jun '21 | — | -$724 | — | — | 7.2% | — | — | — | — |
Valuation over time
How the market has priced CTOR against its own fundamentals since 2024-08 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
P/E
Frequently asked questions
Is CTOR growing its revenue and profit?
See the revenue and net-income charts above for CITIUS ONCOLOGY, INC.'s multi-year trend.
How much debt does CTOR have?
As of FY2025, CITIUS ONCOLOGY, INC. reported — of total debt against $4M of cash; operating income covered interest expense -107.9×.
What is CTOR's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is CTOR's P/E ratio?
As of Sep '26, CITIUS ONCOLOGY, INC. traded at a price-to-earnings ratio of about 68.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.